SPONSORSHIP ALLIANCE NEWS
RefleXion announced the initiation of the BIOGUIDE-X2 clinical study to expand indications for SCINTIX biology-guided radiotherapy. Additionally, the Centers for Medicare and Medicaid (CMS) has expanded reimbursement for SCINTIX therapy to include freestanding cancer centers (FSC), and created a modifier to allow for professional reimbursement for physicians in both FSC and hospital outpatient departments.
On behalf of the Cureus Journal of Medicine (Springer Nature), ZAP is proud to sponsor the Dedicated Cranial Radiosurgery: Clinical Experience with New & Innovative SRS Technologies publishing competition. Looking at novel SRS-exclusive delivery platforms, the program seeks case reports, case series and/or technical reports. All resulting publications will be indexed with Pub-Med Central.
It's a great opportunity to showcase your expertise in state-of-the-art radiosurgery, and educate your peers on new and innovative technologies. And there are $9,000 USD in honoraria to be awarded via crowd-sourced scoring across the top 3 article authors.
For more details, please visit https://www.cureus.com/competitions/CranialSRS. Deadline for draft article submission is April 22, 2025.
Congratulations to Dr. John Adler on his induction into the National Inventors Hall of Fame as part of the class of 2025!
The National Inventors Hall of Fame® celebrates groundbreaking inventors, inspires creativity, and promotes the values of innovation and entrepreneurship.
Discover the full class of 2025 here: https://www.invent.org/inductees/new-inductees
We invite you to submit your radiation therapy case studies that demonstrate the impact and potential of Synchrony® real-time adaptive motion management in any body site. Whether you are working on a Radixact® System or a CyberKnife® System, your insights and findings are invaluable to the medical community.
To participate, please visit the competition page for submission guidelines. The deadline for submissions is Wednesday, March 12th, 2025 and winners will be announced in May 2025. We look forward to your contributions and to celebrating these advancements in radiation therapy together.
Join your fellow Leksell Gamma Knife practitioners for an exclusive opportunity to explore the latest advancements and innovations in Gamma Knife radiosurgery. The call for abstracts for the Leksell Gamma Knife Society Meeting is now open.
The theme for the Leksell Gamma Knife Society Meeting – Stockholm 2025 is ‘Continue to Lead’. We believe it is crucial we all learn from our findings, our challenges and our best practices to pave the way for the future. So, we encourage you to share your most significant findings and submit an abstract. Learn more here: https://tinyurl.com/ycy5j66s
Datopotamab deruxtecan (Dato-DXd) has been granted Breakthrough Therapy Designation (BTD) in the US for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) with disease progression on or after treatment with an EGFR-tyrosine kinase inhibitor (TKI) and platinum-based chemotherapy.
AstraZeneca’s Imfinzi (durvalumab) has been approved in the US for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.
Investment Aims to Further Accelerate Manufacturing, Sales, and Distribution of the ZAP-X Gyroscopic Radiosurgery Platform
ZAP-X demonstrated potent anti-tumor efficacy and adequate tolerability and should be considered a new treatment option for relapsed refractory patients.
As the sponsor of the meeting, Vision RT announces that abstracts are open for the 2025 US SGRT Community Meeting, being held at the Grand Hyatt Hotel in downtown Denver, CO on June 4-6, 2025. This will be an opportunity to share best practices and network with peers in a venue surrounded by the majesty of the Rocky Mountains. We invite you to submit on any surface guidance topic through the Simulation, Planning, Treatment and Dose Visualization steps. Travel grants are available for successful submissions, and the abstract window will close on Monday, February 3, 2025. Attendance to this event will be completely FREE and 100% peer-driven, with all sessions and talks delivered by SGRT users. The three-day event will be made up of an on-site visit to an SGRT expert user center, presentations, workshops, and the latest innovations, as well as real-life case reports.
Smilow Cancer Hospital, from Yale New Haven Health, successfully delivered the world’s first radiotherapy treatment plan that combines different radiotherapy modalities to a patient with metastatic cancer on the RefleXion® X1. With Multi-target Treatment, the X1 platform integrates both SCINTIX® biology-guided radiotherapy and SBRT to treat multiple tumors in one single plan.
Susanne Kluh, a 57-year-old diagnosed with stage 4 non-small cell lung cancer, is grateful for breakthrough technologies like SCINTIX therapy. Following her therapy, she no longer experiences the pain caused from the tumors in her spine and is keen on sharing this new technology and its benefits with others. She is just one of the more than 30 patients treated with SCINTIX therapy since FDA clearance, with more receiving treatment every week. Listen to Susanne's interview, hear from her physician, Dr. Yufei Liu from City of Hope, and from Sam Mazin, our founder and CTO, as they describe this groundbreaking technology.
During ASTRO 2024, RefleXion showcased Multi-target Treatment (MTT), the groundbreaking X1 platform upgrade that allows physicians to combine SCINTIX® biology-guided radiotherapy with conventional stereotactic body radiotherapy (SBRT) in a single plan to treat patients with metastatic disease. Researchers also presented new scientific evidence in 22 presentations during this conference, including four oral presentations, showcasing the RefleXion® X1 machine with SCINTIX therapy.
Finally, non-invasively treat brain tumors. Anywhere. Everywhere. In this on-demand presentation, peer physicians share their knowledge and experience in building high-volume ZAP-X SRS programs. Additionally, discover how others have expanded patient access to SRS with ZAP-X installation sites that were previously inconceivable, yet now more convenient and lower cost. Watch the presentation here.
Combining ZAP-X’s novel gyroscopic mechanics with continuous beam delivery, Dynamic Spherical Delivery is set to redefine SRS efficiency, dose gradient, and conformality. Transcending the innate mechanical shortcomings of multi-purpose radiotherapy systems, for the first time ever, continuous orthogonal beams, spirals, oblique spirals, or any combination become reality. The goal: better treatments in less time.
AstraZeneca’s Tagrisso (osimertinib) has been approved in the US for the treatment of adult patients with unresectable, Stage III epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) whose disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy (CRT). Tagrisso is indicated for patients with exon 19 deletions or exon 21 (L858R) mutations, as detected by a FDA-approved test.